前药的药代动力学研究进展

摘要/Abstract

摘要： 前药是自身无活性,在体内经生物转化后释放出有药效活性的代谢物或原药的化合物。前药设计已成为改善药物的一些不良性质如水溶性低、生物利用度差、半衰期太短及缺乏理想的靶向性等的一种重要手段。然而如何从药物代谢动力学角度评价前药尚缺乏统一的标准。本文对近年来前药的药代动力学研究状况进行了概括总结,并提出如何从吸收、分布、代谢和排泄角度对前药的药代动力学性质进行全面评价。

关键词: 前药, 药物代谢动力学, 转化

Abstract: Prodrugs are chemicals with little or no pharmacological activity, which can be changed to therapeutically active metabolite after undergoing biotransformation in vivo. The design of prodrugs has become an important way to overcome the shortcomings of drugs such as poor solubility, low bioavailability, short elimination half-life, devoid of ideal targets and so on. However, there still lacks criteria to evaluate pharmacokinetic properties of prodrugs. This paper reviews the pharmacokinetic profiles of various types of prodrugs in recent years, and proposes full evaluation from absorption, distribution, metabolism and excretion perspectives.

Key words: Prodrug, Pharmacokinetics, Biotransform

中图分类号:

R969.1

朱胤慈, 孙建国, 彭英, 王广基. 前药的药代动力学研究进展[J]. 中国临床药理学与治疗学, 2012, 17(12): 1433-1440.

ZHU Yin-ci, SUN Jian-guo, PENG Ying, WANG Guang-ji. Research on the pharmacokinetics of prodrugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(12): 1433-1440.

参考文献

[1] 操锋, 平其能, 陈军. 口服前药研究:机遇与挑战[J]. 药学学报, 2008, 43(4): 343-349.
[2] Stella VJ, Himmelstein KJ.Prodrugs and site-specific drug delivery[J]. J Med Chem, 1980, 23(12): 1275-1282.
[3] Testa B.Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps[J]. Curr Opin Chem Biol, 2009, 13(3): 338-344.
[4] Ettmayer P, Amidon GL, Clement B, et al.Lessons learned from marketed and investigational prodrugs[J]. J Med Chem, 2004, 47(10): 2393-2404.
[5] Beaumont K, Webster R, Gardner I, et al.Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientists[J]. Curr Drug Metab, 2003, 4(6): 461-485.
[6] 段艳冰, 黄德虎, 刘实, 等. 磷酸酯化在新药开发中的应用[J].医药导报,2011, 30(8): 1056-1057.
[7] 何亮. 前药的研究进展[J]. 世界临床药物, 2006, 27(1): 55-58.
[8] 李铭东, 吉民. 肿瘤活化前药的研究与应用进展[J]. 药品评价, 2006, 3(3): 206-213.
[9] 易静. 肿瘤的酶-前药疗法[J]. 国外医学肿瘤学分册, 2005, 32(6): 413-416.
[10] Wu KM.A new classification of prodrugs: regulatory perspectives[J]. Pharmaceuticals, 2009, 2(3): 77-81.
[11] 刘昌孝, 主编. 实用药物动力学[M]. 1版.北京: 中国医药科技出版社, 2003:241-254.
[12] Rautio J, Kumpulainen H, Heimbach T, et al.Prodrugs: design and clinical applications[J]. Nat Rev Drug Discov, 2008, 7(3): 255-270.
[13] Testa B.Prodrug research: futile or fertile[J]. Biochem Pharmacol, 2004, 68(11): 2097-2106.
[14] Cundy KC, Sastry S, Luo W, et al.Clinical pharmacokinetics of XP13512, a novel transported prodrug of Gabapentin[J]. J Clin Pharmacol, 2008, 48(12): 1378-1388.
[15] Cundy KC, Branch R, Chernov-Rogan T, et al.XP13512[(±)-1-([(α-lsobutanoyloxyethoxy)carbonyl] aminometgyl)-1-cyclohexane Acetic Acid], a novel Gabapentin prodrug: Ⅰ. Design, Synthesis, Enzymatic conversion to Gabapentin, and transport by intestinal solute transporters[J]. J Pharmacol Exp Ther, 2004, 311(1): 315-323.
[16] Cundy KC, Annamalai T, Bu L, et al.XP13512[(±)-1-([(α-lsobutanoyloxyethoxy) carbonyl]aminometgyl) -1-cyclohexane Acetic Acid], a novel Gabapentin prodrug: Ⅱ. Improved oral bioavailability, dose proportionality, and colonic absorption compared with Gabapentin in rats and monkeys[J]. J Pharmacol Exp Ther, 2004, 311(1): 324-333.
[17] Marathe PH, Kamath AV, Zhang Y, et al.Preclinical pharmacokinetics and in vitro metabolism of brivanib(BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate[J]. Cancer Chemother Pharmacol, 2009, 65(1): 55-66.
[18] Gong J, Gan J, Caceres-Cortes J, et al.Metabolism and disposition of [14C]Brivanib Alaninate after oral administration to rats, monkeys and humans[J]. Drug Metab Dispo, 2011, 39(5): 891-903.
[19] Mekhail T, Masson E, Fischer BS, et al.Metabolism, excretion and pharmacokinetics of oral Brivanib in patients with advanced or metastatic solid tumors[J]. Drug Metab Dispo, 2010, 38(11): 1962-1966.
[20] Jonker DJ, Rosen LS, Sawyer MB, et al.A phase Ⅰstudy to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors[J]. Ann Oncol, 2011, 22(6): 1413-1419.
[21] Park JW, Finn RS, Kim JS, et al.Phase Ⅱ, open-label study of Brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2011, 17(7): 1973-1983.
[22] Chapman TM, Ploker GL, Perry CM.Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection[J]. Drugs, 2004, 64(18): 2101-2124.
[23] Wire MB, Shelton MJ, Studenberg S.Clinical pharmacokinetics and drug interactions of the Amprenavir prodrug[J]. Clin Pharmacokinet, 2006, 45(2): 137-168.
[24] Furfine ES, Baker CT, Hale MR, et al.Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor Amprenavir[J]. Antimicrob Agents Chemother, 2004, 48(3): 791-798.
[25] Falcoz C, Jenkins JM, Bye C, et al.Pharmacokinetics of GW433908, a prodrug of Amprenavir, in healthy male volunteers[J]. J Clin Pharmacol, 2002, 42(8): 887-898.
[26] Browne TR, Kugler AR, Eldon MA.Pharmacology and pharmacokinetics of fosphenytoin[J]. Neurology, 1996, 46(6): S3-S7.
[27] Mahajan A, Singh K, Tandon VR, et al.Diacerein: a new symptomatic slow acting drug for osteoarthritis[J]. Drug Reviews, 2006, 8(3): 173-175.
[28] Barditch-Crovo P, Toole J, Hendrix CW, et al.Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of Adefovir Dipivoxil (9-[2-(bis-pivaloyloxymethyl) -phosphonylmethoxyethyl]adenine) in HIV-infected patients[J]. J Infect Dis, 1997, 176(2): 406-413.
[29] Qaqish RB, Mattes KA, Ritchie DJ.Adefovir Dipivoxil: a new antiviral agent for the treatment of Hepatitis B virus infection[J]. Clin Ther, 2003, 25(12): 3084-3099.
[30] Sobue S, Sekiguchi K, Shimatani K, et al.Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers[J]. J Clin Pharmacol, 2004, 44(3): 284-292.
[31] He G, Massarella J, Ward P.Clinical pharmacokinetics of the prodrug Oseltamivir and its active metabolite Ro 64-0802[J]. Clin Pharmacokinet, 1999, 37(6): 471-484.
[32] Pierra C, Amador A, Benzaria S, et al.Synthesis and pharmacokinetics of Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-Methylcytidine[J]. J Med Chem, 2006, 49(22): 6614-6620.
[33] Ishizuka H, Yoshiba S, Okabe H, et al.Clinical pharmacokinetics of Laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers[J]. J Clin Pharmacol, 2010, 50(11): 1319-1329.
[34] Koyama K, Takahashi M, Nakai N, et al.Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats[J]. Xenobiotica, 2010, 40(3): 207-216.
[35] Hagihara K, Kazui M, Ikenaga H, et al.Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs[J]. Xenobiotica, 2009, 39(3): 218-226.
[36] Farid NA, Smith RL, Gillespie TA, et al.The disposition of Prasugrel, a novel thienopyridine, in humans[J]. Drug Metab Dispo, 2007, 35(7): 1096-1104.
[37] Smith RL, Gillespie TA, Rash TJ, et al.Disposition and metabolic fate of prasugrel in mice, rats, and dogs[J]. Xenobitica, 2007, 37(8): 884-901.
[38] Gustafsson D, Elg M.The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review[J]. Thromb Res, 2003, 109(Suppl 1): S9-15.
[39] Eriksson UG, Bredberg U, Gislen K, et al.Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects[J]. Eur J Clin Pharmacol, 2003, 59(1): 35-43.
[40] Beumer JH, Eisesman JL, Gilbert JA, et al.Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine(THU) prodrug, triacetyl-THU(taTHU), in mice[J]. Cancer Chemother Pharmacol, 2011, 67(2): 421-430.
[41] 周毅, 杨俊, 康仪, 等. 异丙酚前药HX0891和HX-0892在大鼠体内的初步药效学评价[J]. 华西药学杂志, 2012, 27(1): 045-047.
[42] 张明, 顾为, 张天宏, 等. PSI-6130前药的设计、合成及其在大鼠体内的转化评价[J]. 中国药物化学杂志, 2011, 21(5): 335-344.
[43] 黄丽华, 刘志勇, 罗蝉, 等. HPLC-荧光法研究阿德福韦前药的大鼠组织分布[J]. 药物分析杂志, 2011, 31(4): 637-640.
[44] 张锦雯, 孙建国, 王广基, 等. 大黄酸在大鼠和比格犬体内的吸收动力学研究[J]. 中国临床药理学与治疗学, 2010, 15(5): 511-518.
[45] Peng Y, Sun JG, Wang GJ.Pharmacokinetic study of Rhein and its carboxyl-esterification derivatives in rats[J]. Chin J Nat Med, 2009, 7(3): 228-233.
[46] Nicolas P, Tod M, Padoin C, et al.Clinical Pharmacokinetics of Diacerein[J]. Clin Pharmacokinet, 1998, 35(5): 347-359.